NCT05041166
A Study of [13C]Pyruvate as an Imaging Agent for Magnetic Resonance Imaging in Healthy Volunteers
Enrolling by Invitation
PHASE1Ages 18–80InterventionalDiagnosticMemorial Sloan Kettering Cancer CenterInvestigator-initiated
~50 participants
Updated 2026-02-20 on ClinicalTrials.gov
What's tested:Hyperpolarized [13C] Pyruvate
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Signal-to-noise ratios
Measured over 1 day
Conditions
Where it's being run
1 sites across 1 statesNew York1
Study leadership
- Vesselin Miloushev, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age between 18-80
Negative serum or urine pregnancy test for female volunteers of childbearing age and potential (as defined by MSKCC Standards \& Guidelines), from assays obtained \<2 weeks prior to study enrollment. Urine pregnancy tests are only valid for the day of test.
Exclusion
Breast-feeding
History of metabolic (e.g. diabetes) and renal functional disorders.
Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)
Acute major illness (e.g., unstable cardiovascular condition, systemic malignant diseases, etc.).
Standard MRI safety screening will be applied (MRI screening questionnaire); volunteers with MR unsafe devices, or conditional devices where research mode is not allowed, will be excluded.
What this trial measures
- Signal-to-noise ratios1 day
will be used to assess image quality, and to compare the different technical setups. The setup providing the highest SNR will be considered optimal.